Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Oct 23, 2020 (6 years ago)

Felodipine Extended Release Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability samples for the impurity Felodipine Related compound A

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Felodipine Extended Release Tablets, USP 10 mg,100-count bottle, Rx only, Distributed by: Heritage Pharmaceuticals Inc. East Brunswick, NJ 08816 Made in India, NDC 23155-050-01

Affected NDC 23155-0050-01

Compare with the code on your package — it is the most precise check available.

Drug: Felodipine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Felodipine
NDC 23155-0050
10 mg/1 Tablet, Extended Release
Oral
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. Rx
Recalling firm
Heritage Pharmaceuticals Inc
NDC code
23155-050-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0108-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Felodipine recalls

See all

Other recalls by Heritage Pharmaceuticals Inc

All 2020 recalls
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026